Geron Corporation (GERN)
| Market Cap | 740.49M |
| Revenue (ttm) | 183.40M |
| Net Income (ttm) | -79.99M |
| Shares Out | 638.36M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,240,235 |
| Open | 1.160 |
| Previous Close | 1.160 |
| Day's Range | 1.130 - 1.170 |
| 52-Week Range | 1.040 - 4.205 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 3.00 (+158.62%) |
| Earnings Date | Nov 5, 2025 |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]
Financial Performance
In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 158.62% from the latest price.
News
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help
Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, u...
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
Geron Corporation ( GERN) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian -...
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...
Geron Corporation to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it wi...
Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy
Geron Corporation (GERN) is rated BUY due to strong early RYTELO sales, robust financials, and an undervalued stock price near 52-week lows. RYTELO, recently FDA-approved for lower-risk MDS, is drivin...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025...
Geron Corporation Announces Executive Leadership Transitions and Appointments
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commerc...
Making Money In Biotech Stocks
How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ...
Geron to Participate in the 2025 Wells Fargo Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on ...
Geron Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to...
Geron: I Think We've Seen This Movie Before
Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has alre...
Geron Corporation (GERN) Q2 2025 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim...
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...
Geron Appoints Harout Semerjian as President and Chief Executive Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and busi...
Conservative Vision Of A Positive Future For Geron
This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter s...
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)
Geron's RYTELO faces limited revenue potential in a crowded MDS market, with predominantly 3L+ utilization and flat sequential growth. Despite a narrowed net loss, Geron remains unprofitable with no c...
GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm.
Geron Corporation (GERN) Q1 2025 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Ron Maldiver - Investor Relations Dawn Bir - Interim President and Chief Executive Officer...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...